|
|
Article: PTC, CV In Potential $345M Cardiovascular Agreement.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Senior Staff Writer
Less than three months after signing its first major preclinical deal focused on infectious disease, PTC Therapeutics Inc. topped it with a new cardiovascular collaboration worth up to $345 million with CV Therapeutics Inc.
South Plainfield, N.J.-based PTC will apply its Gene Expression Modulation by Small-Molecules (GEMS) technology to develop orally bioavailable small molecules. Together, the companies will select five targets, including those known to raise HDL and be involved in dyslipidemia and diabetes.
"The technology can be applied virtually to any therapeutic area," said Claudia Hirawat, the company's senior vice ...